STAT

APRIL 4, 2024

… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes.  In

Diabetes 286

Diabetes Biosimilars 286

Express Pharma

AUGUST 8, 2024

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.

Biosimilars 102

Biosimilars Diabetes 102

pharmaphorum

JUNE 20, 2025

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 71

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 71

Putting Patients First Blog

JANUARY 27, 2025

The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. To further strengthen these efforts, the NHC recommends that CMS adopt additional measures to ensure broad access to generics, biosimilars, and other cost-effective treatments.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Pharmacy Times

JUNE 4, 2025

USP plans to continue expanding its advanced technology footprint into an additional 8,000 square foot laboratory in 2026. The Advanced Technologies Lab is the latest of USP’s investments in advanced manufacturing technologies. Learn more about USP’s supply chain solutions.

Pharmaceutical Manufacturing 26

Pharmaceutical Manufacturing Pharmacy Technician Compounding Pharmacies Compounding 26

Pharmacy Times

JUNE 10, 2025

Pharmacy schools are expected to graduate 8,000 student pharmacists in 2026…” [Instagram post]. North American Pharmacist Licensure Examination Passing Rates for 2022-2024 Graduates. National Association of Boards of Pharmacy. January 21, 2025. Accessed June 6, 2025. aacpharmacy. March 12, 2025. Accessed June 6, 2025.

Pharmacy Technician 26

Pharmacy Technician Doctor of Pharmacy Compounding Pharmacies Hospitals 26